A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.Xing Zhang, Yifan Zhai, Lichuang Men et al.|Journal of Clinical Oncology|2019Cited by 8
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.Xing Zhang, Yifan Zhai, Xizhi Wen et al.|Journal of Clinical Oncology|2020Cited by 7